DR. INFOvsOpenEvidenceUpdated 16 October 2026

OpenEvidence in France: is it available, and what do French doctors use instead? (2026)

The best OpenEvidence alternative in France is DR. INFO: a clinical AI built in Europe and hosted in the EU that writes a cited answer in French from guidelines and literature, and can be used from France now that OpenEvidence has ended access from the EU. OpenEvidence terminated app access in the EU and the UK on 28 April 2026, citing regulatory uncertainty around European AI rules, and access from French and other European addresses has been blocked since [1][2]. There was never a French version: OpenEvidence answered in English from US-oriented sources. The 241,255 doctors in practice that the Ordre national des médecins counted on 1 January 2025 [3] still have the free national references: the recommandations de bonne pratique of the Haute Autorité de Santé [4], the public drug database maintained by the ANSM [5] and the Vidal monographs [6], all written to be read rather than to answer a question about the patient in front of you. On OpenAI's HealthBench Hard, DR. INFO scored 0.72 against OpenEvidence's 0.49 on the same 100 examples [7][8]. This page is written in English because most French clinicians search for OpenEvidence under its English name; DR. INFO itself answers in French. It covers what happened, what remains in France, and how the options compare for a médecin généraliste or a hospital specialist.

DR. INFO and OpenEvidence, side by side

Available in France

DR. INFO Yes, on the web and the iPhone app

OpenEvidence No, access from the EU ended 28 April 2026

Answers in French

DR. INFO Yes, in the language you ask in

OpenEvidence No, English only

How it answers

DR. INFO A written answer built from retrieved guidelines and literature, each statement cited

OpenEvidence A written answer with citations, US-oriented sources

Data hosting

DR. INFO European Union, under GDPR

OpenEvidence United States

Guideline sources

DR. INFO European and national guidelines, retrieved per question; HAS recommendations are public and can be asked about

OpenEvidence US-centred

Drug information

DR. INFO FDA and EMA authorised sources, EMA SmPC; the ANSM public database and Vidal remain the French references

OpenEvidence US sources

Documentation

DR. INFO Scribe with SOAP notes and discharge letters in the same product

OpenEvidence None

Regulatory status

DR. INFO CE marked medical device under EU MDR 2017/745, which applies directly in France

OpenEvidence Not CE marked

HealthBench Hard (same 100 examples)

DR. INFO 0.72

OpenEvidence 0.49

Cost

DR. INFO Free tier, paid plans

OpenEvidence Was free for verified clinicians

How DR. INFO compares with OpenEvidence

DR. INFO and OpenEvidence on HealthBench Hard

Rubric graded scores on difficult, open ended clinical conversations, from the same 100 example run. Higher is better.

0.250.500.751.000.72DR. INFO0.49OpenEvidence

Source: Ravichandran S, et al. OpenAI’s HealthBench in Action. arXiv:2509.02594.

Frequently asked questions

Is OpenEvidence available in France in 2026?
No. OpenEvidence terminated app access in the EU and the UK on 28 April 2026, and access from French and other European addresses has been blocked since. The company cited regulatory uncertainty around European AI rules. No return date has been announced.
Is there a French version of OpenEvidence?
No. OpenEvidence never answered in French or offered a French interface, and its sources were US-oriented. Searches for OpenEvidence en français lead back to the April 2026 withdrawal. DR. INFO answers in the language you ask in, so a question in French gets a cited answer in French.
Does the OpenEvidence app still work in France?
No. The app can be installed, but sign-in and access from EU addresses have been blocked since April 2026, in the app and in the browser alike. DR. INFO works in the browser at app.drinfo.ai and on the iPhone app, from France without workarounds.
When will OpenEvidence come back to France?
There is no date. The withdrawal was tied to European AI regulation, whose obligations for medical AI phase in through 2027, so a return would be a decision by the company rather than a technical fix. A clinician who needs a cited answer today is better off not waiting for it.
Why did OpenEvidence leave Europe?
OpenEvidence withdrew from the EU and the UK together, citing uncertainty about European AI regulation, including the EU AI Act. Commentary in the medical press has treated the move as a sign of the regulatory divide between US health AI and European rules [9].
What do French doctors use instead of OpenEvidence?
Two kinds of tool. The free French references: the recommandations de bonne pratique and fiches of the Haute Autorité de Santé [4], the Base de données publique des médicaments run by the ANSM [5] and the Vidal monographs [6], all written to be consulted. And DR. INFO, a European clinical AI that answers a clinical question in French with citations you can open, hosts data in the EU, and includes a scribe and discharge letter drafting.
Is DR. INFO the best OpenEvidence alternative for French doctors?
For a clinician who wants what OpenEvidence did, a cited written answer to a clinical question, DR. INFO is the closest fit that can be used from France: it retrieves guidelines and literature for each question, cites every statement, hosts data in the EU, answers in French and scored 0.72 against OpenEvidence's 0.49 on HealthBench Hard.
How does DR. INFO cite its answers?
Each answer is written from documents retrieved for that question, and each statement carries a citation that opens the source: a guideline, a peer reviewed paper, or an FDA or EMA drug document. That makes the answer checkable in the way a colleague's summary is not. In a prospective pilot study published in Cureus in 2026, physicians using DR. INFO at the point of care rated that traceability as part of its value [10].
Can DR. INFO answer questions about HAS recommendations?
HAS recommendations are public documents, so DR. INFO can be asked about them and cites the source it used in the answer; with the country set to France, national recommendations are preferred, and European guidelines from bodies such as the ESC and ESMO are always included. Coverage is broad but not complete for any single body. DR. INFO is not affiliated with the HAS, and the current recommendation on the HAS website remains the version to rely on.
Where is DR. INFO's data hosted, and what does French law require?
DR. INFO is hosted in the European Union under GDPR. France adds a specific rule: personal health data hosted on behalf of a health establishment or professional must be held by a certified hébergeur de données de santé under article L1111-8 of the Code de la santé publique [11]. Asking a clinical question without patient identifiers does not transfer health data. Whether a given use in your establishment involves identifiable patient data, and so falls under HDS and needs an impact assessment, is a decision for your délégué à la protection des données under the CNIL's guidance.
Is DR. INFO free for doctors in France?
There is a free tier for doctors, internes and medical students, with paid plans for heavier use. It works in the browser at app.drinfo.ai and on the iPhone app, from France without restriction.
Does using DR. INFO count towards DPC?
No. DR. INFO is a working tool for daily practice, not a registered training action. Développement professionnel continu credit in France comes only from actions registered with the Agence nationale du DPC. What DR. INFO contributes is the path to the recommendation or the paper behind an answer; the reading and learning remain yours.
Is DR. INFO a certified medical device?
Yes. DR. INFO is CE marked under EU MDR 2017/745 [12], which applies directly in France with the ANSM as the competent authority, and is developed and operated by Synduct GmbH in Munich.

OpenEvidence is not coming back to France on any announced date, there was never a French version, and the HAS recommendations and Vidal were never an answer engine. For a French clinician who wants a cited answer to a clinical question in French, DR. INFO is the tool to try first: built in Europe, hosted in the EU, free to start, and scoring higher than OpenEvidence on the hardest public benchmark of clinical answers.

References

  1. 1.Breaking: OpenEvidence app access terminated in the UK and EU. Telehealth and Telecare Aware. 28 April 2026.
  2. 2.The US-based medical search engine OpenEvidence is down in Europe: a commentary on regulatory complexities. Intelligence-Based Medicine. 2026.
  3. 3.Conseil national de l’Ordre des médecins. Atlas de la démographie médicale en France, situation au 1er janvier 2025. March 2025.
  4. 4.Haute Autorité de Santé. Recommandations de bonne pratique.
  5. 5.ANSM. Base de données publique des médicaments.
  6. 6.Vidal. Monographies et recommandations pour les professionnels de santé.
  7. 7.Ravichandran S, Kumar S, Corga Da Silva R, Romano M, et al. OpenAI’s HealthBench in Action: Evaluating an LLM-Based Medical Assistant on Realistic Clinical Queries. arXiv:2509.02594. 2026.
  8. 8.Arora RK, Wei J, Soskin Hicks R, et al. HealthBench: Evaluating Large Language Models Toward Improved Human Health. OpenAI. 2025.
  9. 9.OpenEvidence exits Europe, highlighting divide in health AI rules. Telehealth.org. 2026.
  10. 10.Corga Da Silva R, Romano M, Mendes T, et al. DR. INFO at the Point of Care: A Prospective Pilot Study of Physician-Perceived Value of an Agentic Artificial Intelligence Clinical Assistant. Cureus. 2026.
  11. 11.Agence du Numérique en Santé. Hébergeurs de données de santé (HDS): certification requirement under article L1111-8 of the Code de la santé publique.
  12. 12.Regulation (EU) 2017/745 of the European Parliament and of the Council on medical devices (EU MDR). Official Journal of the European Union. 2017.